| CAS NO: | 40951-21-1 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Cas No. | 40951-21-1 |
| 别名 | DL-Α-羟基戊二酸二钠 |
| 化学名 | sodium 2-hydroxypentanedioate |
| Canonical SMILES | OC(C([O-])=O)CCC([O-])=O.[Na+].[Na+] |
| 分子式 | C5H6Na2O5 |
| 分子量 | 192.08 |
| 溶解度 | PBS (pH 7.2): 10 mg/ml |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: N/A D-α-Hydroxyglutaric acid, an α-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-α-hydroxyglutaric aciduria. In vitro: In humans the enzyme hydroxyacid-oxoacid transhydrogenase catalyzed the formation of D-α-hydroxyglutaric acid, while D-α-hydroxyglutaric acid is catalyzed by 2-hydroxyglutarate synthase in bacteria. Recent study discovered heterozygous somatic mutations in the genes encoding isocitrate dehydrogenase-1 and -2 (IDH1 and IDH2) and these mutations could disable the enzymes' ability to convert 2-ketoglutarate to D-α-hydroxyglutarate. The authors also found heterozygous germline mutations in IDH2 that alter enzyme residue in patients with D-2-hydroxyglutaric aciduria, a neurometabolic disorder characterized by supraphysiological levels of D-α-Hydroxyglutaric acid [1]. In vivo: Previous animal study demonstrated that the overexpression of the isocitrate dehydrogenase-1 (IDH1) mutation resulted in detectable levels of D-α-Hydroxyglutaric acid in a mouse glioma model that could be measured in vivo and noninvasively by MRS. Results showed that this mouse model system was of potential application in establishing the relationships among D-α-Hydroxyglutaric acid levels and treatment effect, outcomes, as well as other related and necessary variables to validate D-α-Hydroxyglutaric acid as a clinically important biomarker for glioma [2]. Clinical trial: Up to now, D-α-Hydroxyglutaric acid is still in the preclinical development stage. References: |
m.cnreagent.com